Key Highlights

  • Abbott Laboratories (NYSE: ABT) is declining to $84.68 (-2.68%) continuing a relentless downtrend from highs near $136, representing a ~38% peak-to-trough collapse over twelve months
  • Price remains well below both the 21-day EMA ($92.25) and 50-day EMA ($99.02), confirming deeply bearish Moving Average alignment with no signs of recovery
  • RSI-10 at 21.66 with smoothing average at 26.61 signals extreme oversold conditions — however in strong downtrends, oversold can remain oversold for extended periods
  • Volume at 4.73M is elevated on today's decline, reflecting continued distribution pressure with no meaningful accumulation visible
  • Structure shows a relentless series of lower highs and lower lows since the $136 peak, with every attempted recovery swiftly rejected

Trend Structure: Bearish Continuation With No Base Formation

ABT is locked in one of the most persistent downtrends on the NYSE, having made no meaningful attempt to reverse over a twelve-month period. The stock has consistently formed lower highs and lower lows from the mid-2025 peak, with every rally attempt quickly faded by sellers. Price has remained below both the EMA-21 and EMA-50 for months, and critically, both moving averages are now pointing steeply downward — a confirmed Death Cross alignment that signals sellers are in control across all short and medium timeframes. The current decline is not a pullback within a bull trend — it is the trend itself, and there is no technical evidence of a base forming at current levels.

Price Action: Waterfall Decline With Accelerating Momentum

Recent price behaviour highlights a classic waterfall decline pattern with no meaningful support levels holding. ABT has fallen from $136 to $84.68 — nearly $52 per share destroyed — with the most aggressive leg of the decline occurring in recent months as selling pressure accelerated. Every attempted recovery in the $108–$116 zone (November–December 2025) and $96–$100 zone (March 2026) was swiftly rejected at the declining EMAs, reinforcing the pattern of sell-the-rally behaviour. With no visible consolidation base and price printing fresh multi-year lows, the path of least resistance unambiguously points lower toward the $80.00 psychological level and potentially $76–$78 beyond.

Moving Averages: Unambiguously Bearish Death Cross Alignment

The moving average configuration for ABT is as bearish as it gets. Price at $84.68 is trading a massive $7.57 below the EMA-21 and an even more alarming $14.34 below the EMA-50, with both averages sloping aggressively downward and the gap between them widening — a confirmed and sustained death cross. There is no sign of the EMAs flattening or converging, which would be the first prerequisite for any trend Reversal. Any bounce toward the $92 EMA-21 zone should be treated as a shorting opportunity rather than a recovery signal until price can close above both MAs on sustained volume — an outcome that appears distant given current momentum.

Momentum Indicators: Extreme Oversold but Not a Buy Signal

RSI-10 at 21.66 with its smoothing average at 26.61 places momentum in deeply oversold territory — however, this is a dangerous trap for counter-trend buyers. In sustained downtrends, RSI can remain below 30 for weeks or months, as seen in ABT's own February 2026 episode where RSI collapsed to similar levels before a brief dead-cat bounce that was quickly sold into. The RSI smoothing line at 26.61 crossing above the RSI line at 21.66 may generate a minor technical bounce, but without a fundamental catalyst and structural price recovery above $92, any RSI-driven bounce is likely to be shallow and short-lived. No bullish divergence is yet confirmed on the broader trend.

Volume Analysis: Distribution Pattern Intact

Volume at 4.73M is elevated on today's session, and the broader volume profile tells a deeply concerning story — the largest volume spikes over the past six months have consistently coincided with down days and sharp sell-offs, confirming systematic institutional distribution rather than accumulation. There are no visible high-volume reversal candles (such as hammer or bullish engulfing patterns on above-average volume) that would suggest smart money is stepping in to absorb Supply. Until a clear volume-backed accumulation day emerges, the distribution thesis remains dominant.

Key Technical Levels and Scenarios

Resistance Levels

  • $88.00–$89.00 — Immediate overhead resistance (prior support turned resistance)
  • $92.25 — Critical resistance (EMA-21)
  • $99.02 — Major resistance (EMA-50)

Support Levels

  • $83.00–$84.00 — Immediate floor (current price area)
  • $80.00 — Key psychological support
  • $76.00–$78.00 — Extended downside target

Scenarios

  1. Bearish Continuation (Primary Case) — Price fails to hold $84, selling accelerates toward $80 psychological support, with extended target at $76–$78 on any macro or fundamental deterioration.
  2. Dead-Cat Bounce (Secondary Case) — Oversold RSI triggers a technical bounce toward $88–$92, which is quickly faded by sellers re-engaging at the declining EMA-21 — offering a potential short entry.
  3. Trend Reversal (Low Probability) — A sustained close above EMA-21 at $92.25 on very high volume with a fundamental catalyst could signal early stabilisation, but this scenario requires confirmation not yet visible in the data.

Conclusion: Bears Firmly in Control — Oversold Is Not a Bottom

Abbott Laboratories is exhibiting a textbook institutional distribution and waterfall decline pattern, with today's -2.68% drop to fresh lows at $84.68 confirming that sellers remain completely in control. The death cross EMA alignment, relentless lower-highs structure, and distribution volume profile all point to further downside as the primary scenario. While RSI at 21.66 may spark a brief technical bounce, oversold conditions in a strong downtrend are not a sufficient reason to buy — they are a warning that the selling has been both severe and sustained. Bears should watch for any failed rally toward $92 EMA-21 as a re-entry opportunity, while bulls must wait for a decisive structural reclaim above both EMAs before considering any long exposure.